Loading clinical trials...
Loading clinical trials...
The purpose of this study is to determine within the scope of the trial what the maximum tolerated dose (MTD) of lenalidomide in combination with AVD should be.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
University of Cologne
NCT05169515 · Non-Hodgkin Lymphoma
NCT07623850 · Advanced Solid Tumor (Phase 1), Hodgkin Lymphoma, and more
NCT05533775 · Mature B-Cell Non-Hodgkin Lymphoma
NCT05672251 · Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Grade 3b Follicular Lymphoma, and more
NCT07249528 · Non-hodgkin Lymphoma, Multiple Myeloma
1st Dept. of Medicine, Cologne University Hospital
Cologne, North Rhine-Westphalia
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions